CERo Therapeutics Holdings, Inc. Common Stock (CERO) - Net Assets
Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has net assets worth $-30.51 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.90 Million) and total liabilities ($32.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of CERo Therapeutics Holdings, Inc. Common to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-30.51 Million |
| % of Total Assets | -1605.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 852.54 |
CERo Therapeutics Holdings, Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see CERo Therapeutics Holdings, Inc. Common (CERO) total market value.
Annual Net Assets for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual net assets of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. Also explore CERO net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-5.45 Million | -187.48% |
| 2024-12-31 | $-1.89 Million | +95.50% |
| 2023-12-31 | $-42.06 Million | -1803.64% |
| 2022-12-31 | $2.47 Million | -98.55% |
| 2021-12-31 | $170.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CERo Therapeutics Holdings, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8316770300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.11K | % |
| Other Components | $85.39 Million | % |
| Total Equity | $-5.45 Million | 100.00% |
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ProstaLund AB
ST:PLUN
|
$716.78K |
|
Strikewell Energy Corp
V:SKK
|
$717.66K |
|
Tinybuild Inc
LSE:TBLD
|
$717.77K |
|
Kollect on Demand Holding Ab
ST:KOLL
|
$719.15K |
|
Glen Eagle Resources Inc
V:GER
|
$715.41K |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
$715.17K |
|
Satis Group S.A.
WAR:STS
|
$714.73K |
|
SolarWorld Aktiengesellschaft
HM:SWVK
|
$714.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CERo Therapeutics Holdings, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,894,563 to -5,446,462, a change of -3,551,899.
- Net loss of 19,920,262 reduced equity.
- Share repurchases of 395,000 reduced equity.
- New share issuances of 5,075,114 increased equity.
- Other factors increased equity by 11,688,249.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.92 Million | -365.75% |
| Share Repurchases | $395.00K | -7.25% |
| Share Issuances | $5.08 Million | +93.18% |
| Other Changes | $11.69 Million | +214.6% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CERo Therapeutics Holdings, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $23232.71 | $0.01 | x |
| 2022-12-31 | $335.74 | $0.01 | x |
| 2023-12-31 | $-783.74 | $0.01 | x |
| 2024-12-31 | $-15.68 | $0.01 | x |
| 2025-12-31 | $-1.29 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CERo Therapeutics Holdings, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-5.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -0.18% | 0.00% | 0.00x | 1.05x | $-17.40 Million |
| 2022 | -27.05% | 0.00% | 0.00x | 17.16x | $-914.61K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $573.75K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.54 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.38 Million |
Industry Comparison
This section compares CERo Therapeutics Holdings, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $219,658,634
- Average return on equity (ROE) among peers: -31.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CERo Therapeutics Holdings, Inc. Common Stock (CERO) | $-30.51 Million | -0.18% | N/A | $716.31K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $121.06 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $316.23 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.21 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $4.38 Billion |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.